Gaboxadol丨CAS 64603-91-4

Gaboxadol (CAS 64603-91-4) is a pharmacologically active compound primarily used in neuroscience and pharmaceutical research. It functions as a selective agonist of extrasynaptic GABAA_AA​ receptors, particularly targeting the δ-subunit-containing receptor subtypes. Its applications include the study of sleep regulation, anxiety, epilepsy, and neurodegenerative disorders due to its ability to modulate tonic inhibitory signaling in the central nervous system. Gaboxadol is also employed in preclinical and clinical research to explore therapeutic interventions for insomnia, cognitive disorders, and mood regulation. Additionally, it serves as a reference compound for the development of novel GABAergic drugs and as a tool in receptor pharmacology studies to elucidate GABAA_AA​ receptor subtype functions.

The benefits of Gaboxadol stem from its selective pharmacological profile and potent modulation of extrasynaptic GABAA_AA​ receptors. Unlike traditional benzodiazepines, it enhances tonic inhibition without causing widespread sedation or tolerance, making it valuable for studying sleep architecture and neuronal excitability. Its chemical stability and defined stereochemistry facilitate reproducible results in biological assays. Gaboxadol's high specificity allows researchers to differentiate between synaptic and extrasynaptic GABAergic pathways, providing precise mechanistic insights. Furthermore, it is amenable to formulation and experimental design in both in vitro and in vivo studies, supporting a broad range of neuropharmacological investigations.